Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide.
OBJECTIVE
We compared serial measurements of inflammatory mediators and markers in infants treated with inhaled nitric oxide or placebo to assess the effects of inhaled nitric oxide therapy on lung inflammation during bronchopulmonary dysplasia. We investigated relationships between respiratory severity scores and airway concentrations of inflammatory markers/mediators.


METHODS
As part of the Nitric Oxide (to Prevent) Chronic Lung Disease trial, a subset of 99 infants (52 placebo-treated infants and 47 inhaled nitric oxide-treated infants; well matched at baseline) had tracheal aspirate fluid collected at baseline, at 2 to 4 days, and then weekly while still intubated during study gas treatment (minimum of 24 days). Fluid was assessed for interleukin-1beta, interleukin-8, transforming growth factor-beta, N-acetylglucosaminidase, 8-epi-prostaglandin F2alpha, and hyaluronan. Results were normalized to total protein and secretory component of immunoglobulin A.


RESULTS
At baseline, there was substantial variability of each measured substance and no correlation between tracheal aspirate fluid levels of any substance and respiratory severity scores. Inhaled nitric oxide administration did not result in any time-matched significant change for any of the analytes, compared with the placebo-treated group. There was no correlation between any of the measured markers/mediators and respiratory severity scores throughout the 24 days of study gas administration. In the posthoc analysis of data for inhaled nitric oxide-treated infants, there was a difference at baseline in 8-epi-prostaglandin F2alpha levels for infants who did (n = 21) and did not (n = 26) develop bronchopulmonary dysplasia at postmenstrual age of 36 weeks.


CONCLUSIONS
Inhaled nitric oxide, as administered in this study, seemed to be safe. Its use was not associated with any increase in airway inflammatory substances.
Truog
William E
WE
Department of Pediatrics, Section of Neonatology, Children's Mercy Hospitals and Clinics, University of Missouri-Kansas City School of Medicine, 2401 Gillham Rd, Kansas City, MO 64108, USA. wtruog@cmh.edu
Ballard
Philip L
PL
Norberg
Michael
M
Golombek
Sergio
S
Savani
Rashmin C
RC
Merrill
Jeffrey D
JD
Parton
Lance A
LA
Cnaan
Avital
A
Luan
Xianqun
X
Ballard
Roberta A
RA
D000280:Administration, Inhalation; D015415:Biomarkers / Q000032:analysis; D001997:Bronchopulmonary Dysplasia / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016207:Cytokines / Q000032:analysis*; D015237:Dinoprost / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D018836:Inflammation Mediators / Q000032:analysis*; D053583:Interleukin-1beta / Q000032:analysis; D016209:Interleukin-8 / Q000032:analysis; D008297:Male; D009569:Nitric Oxide / Q000627:therapeutic use*; D011379:Prognosis; D012016:Reference Values; D015203:Reproducibility of Results; D012121:Respiration, Artificial / Q000379:methods; D012680:Sensitivity and Specificity; D014132:Trachea / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000032:analysis; D016896:Treatment Outcome
D015415:Biomarkers; D016207:Cytokines; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D016209:Interleukin-8; D016212:Transforming Growth Factor beta; D009569:Nitric Oxide; D015237:Dinoprost